Sarepta Therapeutics Inc
NASDAQ: SRPT
$127.10
+$2.09 (+1.7%)
Closing Price on September 19, 2024
SRPT Articles
Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.
Published:
Last Updated:
Sarepta Therapeutics Inc. (NASDAQ: SRPT) has seen more than its fair share of volatility in the market of late. Now shares are surging after it has reached a compromise with the U.S. Food and Drug...
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include First Data, General Electric, Sarepta Therapeutics, Western Digital, Walgreens Boots Alliance and Zillow.
Published:
Last Updated:
Sarepta Therapeutics and Globalstar are among the companies that punished shareholder the most this past week.
Published:
Last Updated:
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares saw a handy gain on Wednesday following an analyst upgrade from Janney Montgomery Scott.
Published:
Last Updated:
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
Published:
Last Updated:
Apple, Twitter and other companies punished shareholders last week, and analysts expect more earnings disappointments going forward.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday morning include Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital and Whiting Petroleum.
Published:
Last Updated:
April 26, 2016: Here are four stocks trading with relatively heavy volume among 14 equities making new 52-week lows in Tuesday’s session. NYSE advancing stocks led decliners by about 3 to 1 while...
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Broadcom, Caterpillar, Sirius XM, Newmont, Palo Alto, Perrigo, Sarepta and Xerox.
Published:
Last Updated:
Although the markets have made their comeback, some stocks are still slowing that recovery and punishing their shareholders. Last week that included Netflix and Sarepta Therapeutics.
Published:
Last Updated:
Sarepta Therapeutics shares got crushed on Thursday and then exploded on Friday following the FDA view on its Duchenne muscular dystrophy treatment.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include ArcelorMittal, Boeing, Intel, Johnson & Johnson, Schlumberger, Yahoo and Vivint Solar.
Published:
Last Updated:
After a week when the indexes finally fought their way back to even for 2016, one probably would think that insiders would be selling the huge rally. Just the opposite happened.
Published:
Last Updated:
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.
Published:
Last Updated: